Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis

Annals of Surgical Oncology

Volumn 23, Issue 3, 2016, Pages 849-855

  Chang, Shih Ching ^a,b   Lin, Pei Ching ^c   Lin, Jen Kou ^a,b   Lin, Chien Hsing ^d   Yang, Shung Haur ^a,b   Liang, Wen Yi ^a   Chen, Wei Shone ^a,b   Jiang, Jeng Kai ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN; B RAF KINASE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOINOSITOL 3 KINASE; PIK3CA PROTEIN; PROTEIN; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; WNT PROTEIN; ONCOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; COLORECTAL CANCER; DESCENDING COLON; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MUTATION RATE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHENOTYPE; RECTUM CANCER; SURVIVAL; VERY ELDERLY; ADENOCARCINOMA, MUCINOUS; COLORECTAL NEOPLASMS; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; SURVIVAL RATE;

EID: 84957846494     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4899-z     Document Type: Article

References (37)

1. The Department of Health. Healthy statistics: Cancer Registry Annual Report in Taiwan Area. Taiwan, R.O.C.: The Department of Health, the Executive Yuan, 2007.
2. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079–99.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–67.
4. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. NEnglJ Med. 1988;319(9):525–32.
5. Cunningham JM, Kim CY, Christensen ER, et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J HumGenet. 2001;69(4):780–90.
6. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. NEnglJ Med. 2009;361(25):2449–60.
7. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58.
8. Garraway LA, Lander ES. Lessons from the Cancer Genome. Cell. 2013;153(1):17–37.
9. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719–24.
10. Tomasetti C, Vogelstein B, Parmigiani G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. ProcNatlAcadSciUSA. 2013;110(6):1999–2004.
11. Casey G, Conti D, Haile R, Duggan D. Next generation sequencing and a new era of medicine. Gut. 2013;62(6):920–32.
12. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113–30.
13. Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. ClinCancer Res. 2012;18(6):1506–12.
14. Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105(15):1151–6.
15. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.
16. Lin JK, Lin PC, Lin CH, et al. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. AnnSurgOncol. 2014;21(Suppl 4):680–6.
17. Arcila M, Lau C, Nafa K, Ladanyi M. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. JMolDiagn. 2011;13(1):64–73.
18. Chang SC, Lin JK, Yang SH, Wang HS, Li AF, Chi CW. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer. 2006;118(7):1721–7.
19. Missiaglia E, Jacobs B, D’Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995–2001.
20. Shen Y, Wang J, Han X, et al. Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoSOne. 2013;8(12):e81628.
21. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61(6):847–54.
22. Albuquerque C, Baltazar C, Filipe B, et al. Colorectal cancers show distinct mutation spectra in members of the canonical WNT signaling pathway according to their anatomical location and type of genetic instability. Genes Chromosomes Cancer. 2010;49(8):746–59.
23. Dejea CM, Wick EC, Hechenbleikner EM, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. ProcNatlAcadSci USA. 2014;111(51):18321–6.
24. Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota dysbiosis is associated with colorectal cancer. Front Microbiol. 2015;6:20.
25. Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014;74(5):1311–8.
26. Leystra AA, Deming DA, Zahm CD, et al. Mice expressing activated PI3K rapidly develop advanced colon cancer. Cancer Res. 2012;72(12):2931–6.
27. Yu M, Trobridge P, Wang Y, et al. Inactivation of TGF-beta signaling and loss of PTEN cooperate to induce colon cancer in vivo. Oncogene. 2014;33(12):1538–47.
28. Riemer P, Sreekumar A, Reinke S, et al. Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by Beta-catenin activity. Oncogene. 2015;34(24):3164–75.
29. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet. 2008;40(5):600–8.
30. Ogino S, Liao X, Imamura Y, et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013;105(23):1789–98.
31. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. NEnglJ Med. 2012;367(17):1596–606.
32. Mouradov D, Domingo E, Gibbs P, et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am JGastroenterol. 2013;108(11):1785–93.
33. Warren RS, Atreya CE, Niedzwiecki D, et al. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. ClinCancer Res. 2013;19(20):5777–87.
34. Yu J, Wu WK, Li X, et al. Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut. 2015;64(4):636–45.
35. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148(1):77–87.e2.
36. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBOMolMed. 2010;2(5):146–58.
37. Russo AL, Borger DR, Szymonifka J, et al. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 2014;120(10):1482–90.